Neal D. Shore, MD : Episode 3

Video

Reassessing Trial Endpoints for CRPC

Related Videos
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Brian I. Rini, MD, FASCO
Marc-Oliver Grimm, MD
Marc Machaalani, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Razane El Hajj Chehade, MD
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Antonio Cigliola, MD
Brian I. Rini, MD, FASCO
Related Content
Christian Behrenbruch PhD, MBA
July 24th 2024

FDA Accepts the New Drug Application for TLX007-CDx Kit in Prostate Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Kassem Faraj, MD, of Michigan Medicine
July 22nd 2024

340B Drug Pricing Program Ostensibly Improves Cancer Care but Carries Unforeseen Consequences

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Razane El Hajj Chehade, MD
July 18th 2024

Clear Cell Histology Associated With Increased Risk of irAEs in Metastatic RCC

Toni Choueiri, MD
July 18th 2024

Nivolumab/Tivozanib Fails to Improve PFS in Advanced RCC After Prior Immune Checkpoint Inhibition